Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz begins Tavist-D cold indication television advertising week of Nov. 11.

This article was originally published in The Tan Sheet

Executive Summary

SANDOZ TAVIST-D COLD INDICATION ADVERTISING KICKS OFF NOV. 11 and continues the Tavist theme of highlighting 12-hour relief. Sandoz received FDA approval of a common cold indication for the antihistamine Tavist-1 and the antihistamine/decongestant Tavist-D on Oct. 31 ("The Tan Sheet" Nov. 4, In Brief). The products, which contain 1.34 mg clemastine fumarate, are the first antihistamines to carry the indication and the only OTCs that contain clemastine fumarate.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086363

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel